Analysis

Viking Therapeutics, Inc. (VKTX) Stock Analysis

Viking Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to VKTX.

websiteVKTX/analysis/VKTX

Viking Therapeutics, Inc.

Viking Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to VKTX.

Stock profile

Ticker

VKTX

Asset type

Stock

Market cap

$3.34B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Viking Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • VKTX primary listing
  • 1VT
  • A12GD6
  • 1VKTX
  • 0VQA

Latest Viking Therapeutics, Inc. news

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders...

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorde...

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders...

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorde...

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 DiabetesSAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc.

Research sections

Valuation

Review valuation context for Viking Therapeutics, Inc..

Future growth

Review future growth context for Viking Therapeutics, Inc..

Past performance

Review past performance context for Viking Therapeutics, Inc..

Financial health

Review financial health context for Viking Therapeutics, Inc..

Dividend

Review dividend context for Viking Therapeutics, Inc..

Management

Review management context for Viking Therapeutics, Inc..

Ownership

Review ownership context for Viking Therapeutics, Inc..

Other information

Review other information context for Viking Therapeutics, Inc..

Community

Review community context for Viking Therapeutics, Inc..